Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children

    loading  Checking for direct PDF access through Ovid


We conducted a phase I clinical trial (clinicaltrials.gov identifier, NCT00641017) of the experimental live-attenuated human parainfluenza virus type 1 (HPIV-1) vaccine rHPIV-1/84/del 170/942A sequentially in 3 groups: adults, HPIV-1–seropositive children, and HPIV-1–seronegative children, the target population for vaccination. rHPIV-1/84/del 170/942A was appropriately restricted in replication in adults and HPIV-1–seropositive children but was overattenuated (ie, insufficiently infectious and immunogenic) for HPIV-1–seronegative children.

Related Topics

    loading  Loading Related Articles